Exercise in Sjogren, Myositis and Takayasu's Arteritis
|ClinicalTrials.gov Identifier: NCT01501019|
Recruitment Status : Unknown
Verified February 2016 by Bruno Gualano, University of Sao Paulo.
Recruitment status was: Recruiting
First Posted : December 29, 2011
Last Update Posted : February 19, 2016
Exercise may improve physical capacity and health parameters in Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis.
Therefore, this study aims to investigate the role of an exercise training program in patients with Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis.
|Condition or disease||Intervention/treatment||Phase|
|Primary Sjogren´s Syndrome Myositis||Other: Exercise training||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effects of Exercise Training in Primary Sjogren´s Syndrome, Myositis and Takayasu's Arteritis|
|Study Start Date :||October 2011|
|Estimated Primary Completion Date :||July 2016|
|No Intervention: Sjogren and Myositis Control (no control for takayasu's)|
|Experimental: Sjogren, Myositis and Takayasu's Trained||
Other: Exercise training
"Sjöegren arm": 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.
"Myositis arm": 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.
"Takayasu's arteritis arm": 30-50 minutes of aerobic, twice a week, moderate intensity.
- Aerobic Capacity [ Time Frame: Twelve weeks ]Maximum Oxygen Consumption (VO2Max)
- Muscle strength [ Time Frame: Twelve weeks ]
- Quality of life [ Time Frame: Twelve weeks ]
- Serum anti-inflammatory cytokines [ Time Frame: Twelve weeks ]Interleukin-10
- Serum pro-inflammatory cytokines [ Time Frame: Twelve weeks ]Interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a)
- Serum inflammatory markers [ Time Frame: Twelve weeks ]erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), aldolase
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01501019
|University of Sao Paulo School of Medicine Clinical Hospital||Recruiting|
|Sao Paulo, Brazil, 05403-010|
|Contact: Thalita Blasques Dassouki, MSc 55 11 2661-8022 firstname.lastname@example.org|
|Principal Investigator: Ana Lucia Sa Pinto, PhD|
|Sub-Investigator: Bruno Gualano, PhD|
|Sub-Investigator: Fernanda R Lima, PhD|
|Sub-Investigator: Hamilton Roschel, PhD|
|Sub-Investigator: Sandra G Pasoto, PhD|